Navigation

Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab [ID490]

Bevacizumab for the treatment of platinum-sensitive or partially platinum-sensitive recurrent advanced ovarian cancer (including fallopian tube and primary peritoneal cancer)

Status: History
Expected date of issue: May 2013
Referral date: September 2011
Process: STA
Notes:

Scoped within Batch 19

Topic area:
  • Cancer
  • Gynaecology, pregnancy and birth
 

NICE project team

Executive Lead: TBC
Technical Lead: Helen Tucker
Communications manager: Laura Gibson
Project manager: Bijal Joshi
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 24 September 2012
1st appraisal committee meeting: 08 January 2013
2nd appraisal committee meeting 05 March 2013
Top


 

Consultees and commentators

To be confirmed

Top


 

Key documents

This page was last updated: 24 May 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.